Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Current Liabilities (2022 - 2025)

Stoke Therapeutics has reported Total Current Liabilities over the past 4 years, most recently at $57.9 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $57.9 million for Q4 2025, up 44.49% from a year ago — trailing twelve months through Dec 2025 was $57.9 million (up 44.49% YoY), and the annual figure for FY2025 was $57.9 million, up 44.49%.
  • Total Current Liabilities for Q4 2025 was $57.9 million at Stoke Therapeutics, up from $41.7 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for STOK hit a ceiling of $57.9 million in Q4 2025 and a floor of $21.8 million in Q2 2023.
  • Median Total Current Liabilities over the past 4 years was $33.6 million (2023), compared with a mean of $35.8 million.
  • Biggest five-year swings in Total Current Liabilities: fell 21.02% in 2023 and later surged 103.76% in 2024.
  • Stoke Therapeutics' Total Current Liabilities stood at $31.4 million in 2022, then decreased by 1.83% to $30.8 million in 2023, then rose by 29.97% to $40.1 million in 2024, then surged by 44.49% to $57.9 million in 2025.
  • The last three reported values for Total Current Liabilities were $57.9 million (Q4 2025), $41.7 million (Q3 2025), and $38.7 million (Q2 2025) per Business Quant data.